## **Product** Data Sheet

# Puromycin-d<sub>3</sub>

Molecular Weight: 474.53

Target: Bacterial; Antibiotic; Isotope-Labeled Compounds

Pathway: Anti-infection; Others

Storage: Powder -20°C 3 years

4°C 2 years -80°C 6 months

In solvent -80°C 6 months -20°C 1 month

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (210.73 mM; Need ultrasonic)

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 2.1073 mL | 10.5367 mL | 21.0735 mL |
|                              | 5 mM                          | 0.4215 mL | 2.1073 mL  | 4.2147 mL  |
|                              | 10 mM                         | 0.2107 mL | 1.0537 mL  | 2.1073 mL  |

Please refer to the solubility information to select the appropriate solvent.

#### **BIOLOGICAL ACTIVITY**

| Description               | Puromycin- $d_3$ is the deuterium labeled Puromycin. Puromycin dihydrochloride is the dihydrochloride salt of puromycin. Puromycin is an aminoglycoside antibiotic that inhibits protein synthesis.  |  |
|---------------------------|--|--|
| IC <sub>50</sub> & Target | Aminoglycoside   |  |
| In Vitro                  | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only. |  |

#### **CUSTOMER VALIDATION**

• Proc Natl Acad Sci U S A. 2023 Apr 11;120(15):e2209435120.

• Int J Biochem Cell Biol. 2023 Oct 28, 106491.

See more customer validations on  $\underline{www.MedChemExpress.com}$ 

#### **REFERENCES**

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
- [2]. Nathans D, et al. Puromycin inhibition of protein synthesis: incorporation of puromycin intopeptide chains. Proc Natl Acad Sci U S A. 1964 Apr;51:585-92.
- [3]. Miyamoto-Sato E, et al. Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000 Mar 1;28(5):1176-82.
- [4]. Schmidt EK, et al. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009 Apr;6(4):275-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com